Photonis Scientific, Inc.
23.5.2023 15:02:26 CEST | ACCESS Newswire | Press release
Visit Photonis at booth #407 during the 71st ASMS Conference
STURBRIDGE, MA / ACCESSWIRE / May 23, 2023 / Photonis has announced that the company will be exhibiting at the 71st American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, taking place June 4 - June 8, 2023, at the George R. Brown Convention Center in Houston, TX.
Photonis can be found at booth 407 in the exhibitor hall. Attendees are encouraged to meet and speak to the company's diverse team of technical experts and learn more about how their industry-leading MS Detection Technology will benefit new applications in Mass Spectrometry due to unprecedented performance levels.
At this occasion, Photonis, the leaders in Time-of-Flight (TOF) detection technologies, will showcase their latest advancements in TOF detection with additions to their existing detector platforms - the APTOF and BPTOF Series.
Photonis presents the APTOF A300, a capacitively-coupled, compact assembly detector designed for small footprint and/or benchtop TOF systems. The APTOF A300 integral AC-coupled high voltage isolation prevents damage to the digitizer and provides MS Instrument manufacturers with significant cost savings.
In parallel, the company will introduce the BPTOF B380, an optically coupled Bi-Polar TOF detector with never-before-seen lifetime benefits, based on a patented technology from Photonis.
Ulrich Laupper, President and General Manager of Photonis' Ultimate Detection Business Unit:
"We are excited to introduce the next generation of Time-of-Flight detection technology at this year's ASMS Conference. Photonis is committed to extensive investments into Research and Development activities in order to provide our industry partners market-leading detector solutions. The APTOF A300 and BPTOF B380 provide mass spectrometry instrument manufacturers an unmatched cost-of-ownership value proposition. In addition, it also enables them to offer new advanced applications to their end users. We are very proud to be part of the ASMS community and contribute to advance science and quality of life with our technologies."
Photonis' Time-of-Flight detectors support some of the world's most sensitive TOF-MS applications. Their patented technologies and distinct Microchannel Plates ensure optimum temporal resolution, excellent mass sensitivity, unmatched lifetime and superb dynamic range; enabling mass spectrometers to be optimized with the best detector on the market, no matter the analysis requirements. Photonis specializes in working in partnership with TOF-MS Instrument designers to understand the requirements needed in each instrument to provide the longest-lasting, accurate detectors specifically designed for each instrument.
About Photonis
Photonis is a market-leading provider of technologies used in the detection and amplification of photons, ions, electrons, and neutrons. We innovate and engineer the highest quality technology solutions for integration into a wide variety of applications, such as mass spectrometry, night vision optics, digital cameras, nuclear instrumentation, life-science and physics research, space exploration, and many others. With over 80 years of experience in partnering with our customers to provide the world's leading detection systems, Photonis has the experience to meet the specific challenges of the many markets we serve.
For more information, please contact us or visit us at booth #407 during the conference.
Contact Information
Nicole Poirier
Marketing Manager
n.poirier@usa.photonis.com
SOURCE: Photonis
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/756322/Photonis-Expands-Market-Leading-Mass-Spectrometry-Detection-Technology
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release
Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a
IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release
New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
